Reneuron Share News (RENE)
RENE Share
RENE Share
RENE Share
RENE Share
RENE
RENE Share
RENE Level 2
RENE Live
RENE Broker
RENE Directors
RENE Financial
RENE
RENE Short
RENE
Last checked at -
Wed, 14th Jul 2021 15:15
ReNeuron Group PLC - Bridgend, Wales-based developer of cell-based therapeutics - Hires Barbara Staehelin as senior independent non-executive director, starting immediately. Staehelin is a member of the Investment Committee at Swiss health insurance firm Assura Holding SA.
Current stock price: 103.89 pence
Year-to-date change: up 26%
By Tom Waite; thomaslwaite@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Stem cell therapy group Reneuron said it remains on track with the first patients having been dosed in two its clinical trials. The phase II trial for the ReN001 cell therapy candidate for stroke disability and the phase I trail for ReN009 cell therapy candidate for critical limb ischaemia have bot
Read more
Last checked at